Bottom line
SWHFX vs RYHIX: the short answer
SWHFX (Schwab Health Care Fund) and RYHIX (Health Care Fund) share a meaningful slice of their top holdings — about 66% by weight.
SWHFX is cheaper at 0.8% vs 1.38% — a difference of $58 a year per $10,000 invested.
Over five years, SWHFX returned +6.5% a year vs +5.1% for RYHIX.
Updated Nov 19, 2026
SWHFX vs RYHIX side by side
| SWHFX | RYHIX | |
|---|---|---|
| Type | Mutual fund | Mutual fund |
| Fund family | Schwab | Guggenheim |
| Category | Health Care Sector | Health Care Sector |
| Expense ratio | 0.8% | 1.38% |
| Annual cost per $10k | $80 | $138 |
| 10-yr cost on $10k (prospectus) | $990 | $1,709 |
| Max front load | — | — |
| 12b-1 fee | 0% | 0% |
| 1-yr return | +15.9% | +14.4% |
| 5-yr return (annualized) | +6.5% | +5.1% |
| 10-yr return (annualized) | +8.1% | +7.9% |
| Best quarter | +15.3% | +18.7% |
| Worst quarter | −12.1% | −14.4% |
| Net assets (fund) | $642.3M | $19.4M |
| Number of holdings | 80 | 135 |
| Portfolio turnover | 41% | 244% |
| Returns as of | Dec 31, 2025 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | SWHFX | RYHIX | Difference |
|---|---|---|---|
| 2025 | +15.9% | +14.4% | +1.5% |
| 2024 | +0.1% | +0.6% | −0.5% |
| 2023 | +0.7% | +5.8% | −5.2% |
| 2022 | −4.7% | −11.6% | +6.9% |
| 2021 | +23.3% | +19.2% | +4.1% |
| 2020 | +12.9% | +18.9% | −6.1% |
| 2019 | +17.6% | +22.8% | −5.1% |
| 2018 | +4.0% | +1.6% | +2.4% |
| 2017 | +20.2% | +23.5% | −3.3% |
| 2016 | −4.4% | −9.4% | +5.0% |
Source: Fund prospectus bar charts
Holdings overlap
16 of SWHFX's top 25 holdings also appear in RYHIX's top 25.
| Holding | SWHFX | RYHIX |
|---|---|---|
| Eli Lilly & Co | 13.92% | 3.63% |
| Johnson & Johnson | 6.94% | 2.88% |
| AbbVie Inc | 5.81% | 2.52% |
| Merck & Co Inc | 4.98% | 2.04% |
| UnitedHealth Group Inc | 4.74% | 2.22% |
| Gilead Sciences Inc | 3.24% | 1.39% |
| Amgen Inc | 2.58% | 1.56% |
| Bristol-Myers Squibb Co | 2.44% | 1.22% |
| Thermo Fisher Scientific Inc | 2.16% | 1.61% |
| Stryker Corp | 2.11% | 1.21% |
| Vertex Pharmaceuticals Inc | 1.89% | 1.34% |
| Boston Scientific Corp | 1.60% | 0.86% |
| Abbott Laboratories | 1.60% | 1.42% |
| Cigna Group/The | 1.51% | 0.94% |
| Danaher Corp | 1.47% | 1.30% |
Source: SEC Form N-PORT
SWHFX top 10
- Eli Lilly & Co — 13.92%
- Johnson & Johnson — 6.94%
- AbbVie Inc — 5.81%
- Merck & Co Inc — 4.98%
- UnitedHealth Group Inc — 4.74%
- Gilead Sciences Inc — 3.24%
- Novartis AG — 2.92%
- Amgen Inc — 2.58%
- Bristol-Myers Squibb Co — 2.44%
- Medtronic PLC — 2.29%
RYHIX top 10
- Eli Lilly & Company — 3.63%
- Johnson & Johnson — 2.88%
- Abbvie Inc — 2.52%
- Unitedhealth Group Inc — 2.22%
- Merck & Company Inc — 2.04%
- Thermo Fisher Scientific Inc — 1.61%
- Amgen Inc — 1.56%
- Abbott Laboratories — 1.42%
- Gilead Sciences Inc — 1.39%
- Vertex Pharmaceuticals Inc — 1.34%
FAQ
What is the difference between SWHFX and RYHIX?
Which is cheaper, SWHFX or RYHIX?
Should I own both SWHFX and RYHIX?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.